FDA Twitter Policy Offers Loophole For Promoting Black-Box Drugs
This article was originally published in The Pink Sheet Daily
Executive Summary
What you might have missed in FDA’s social media guidance: “Reminder-like” promotion utilizes “one-click” rule, allowing companies to promote drugs with excessive risk in space limited Internet and social media platforms.
You may also be interested in...
FDA’s Twitter Formula Allows Tweets About Products Without Excessive Risks
FDA’s draft guidance on presenting product information on social media platforms with character space limitations includes an equation for sending a tweet.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.
Bernie Gets Mostly Pharma-Friendly Drug Pricing Results
Changes to inhaler pricing may be more ‘business as usual’ for the drug industry than the Vermont senator wants to let on. FTC, meanwhile, is keeping the patent pressure on Teva, the only inhaler manufacturer to not act following Sanders’ investigation.